Marie Madeleine M Hidjo, Zedias Chikwambi, Gift Ngwende, Jonathan A Matenga, Collen Masimirembwa
{"title":"津巴布韦黑人队列中的华法林药物遗传学：一项观察性前瞻性研究。","authors":"Marie Madeleine M Hidjo, Zedias Chikwambi, Gift Ngwende, Jonathan A Matenga, Collen Masimirembwa","doi":"10.2217/pgs-2023-0089","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. <b>Methods:</b> <i>CYP2C9*5</i>, <i>CYP2C9*6</i>, <i>CYP2C9*8</i> and <i>CYP2C9*11</i> and <i>VKORC1</i> c. 1639 G>A variations were observed in 62 study patients. <b>Results & Conclusion:</b> Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on <i>CYP2C9*2</i> and <i>CYP2C9*3</i> only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants <i>CYP2C9*5</i>, <i>CYP2C9*6</i> and <i>CYP2C9*11</i>, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"24 10","pages":"529-538"},"PeriodicalIF":1.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621760/pdf/","citationCount":"0","resultStr":"{\"title\":\"Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.\",\"authors\":\"Marie Madeleine M Hidjo, Zedias Chikwambi, Gift Ngwende, Jonathan A Matenga, Collen Masimirembwa\",\"doi\":\"10.2217/pgs-2023-0089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. <b>Methods:</b> <i>CYP2C9*5</i>, <i>CYP2C9*6</i>, <i>CYP2C9*8</i> and <i>CYP2C9*11</i> and <i>VKORC1</i> c. 1639 G>A variations were observed in 62 study patients. <b>Results & Conclusion:</b> Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on <i>CYP2C9*2</i> and <i>CYP2C9*3</i> only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants <i>CYP2C9*5</i>, <i>CYP2C9*6</i> and <i>CYP2C9*11</i>, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.</p>\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":\"24 10\",\"pages\":\"529-538\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621760/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0089\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0089","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
Aim: A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. Methods:CYP2C9*5, CYP2C9*6, CYP2C9*8 and CYP2C9*11 and VKORC1 c. 1639 G>A variations were observed in 62 study patients. Results & Conclusion: Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on CYP2C9*2 and CYP2C9*3 only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants CYP2C9*5, CYP2C9*6 and CYP2C9*11, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.
期刊介绍：
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
